Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Harlem Hospital Center
mi
from
New York, NY
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Harlem Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Carolinas Medical Center
mi
from
Charlotte, NC
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
University of North Texas Health Science Center
mi
from
Fort Worth, TX
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
University of North Texas Health Science Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Michael Debakey Veterans Affairs Medical Center
mi
from
Houston, TX
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Michael Debakey Veterans Affairs Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Audi L. Murphy VA Hospital
mi
from
San Antonio, TX
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Audi L. Murphy VA Hospital
mi
from
San Antonio, TX
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Seattle King County Health Department
mi
from
Seattle, WA
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Seattle King County Health Department
mi
from
Seattle, WA
Click here to add this to my saved trials
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated:  3/15/2018
Universidade Federal do Rio de Janeiro
mi
from
Rio de Janeiro,
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Status: Enrolling
Updated: 3/15/2018
Universidade Federal do Rio de Janeiro
mi
from
Rio de Janeiro,
Click here to add this to my saved trials
Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells
Status: Enrolling
Updated:  3/16/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells
Status: Enrolling
Updated: 3/16/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
"Solana™ Trichomonas Assay Field Study"
"Solana™ Trichomonas Assay Field Study"
Status: Enrolling
Updated:  3/16/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
"Solana™ Trichomonas Assay Field Study"
"Solana™ Trichomonas Assay Field Study"
Status: Enrolling
Updated: 3/16/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
"Solana™ Trichomonas Assay Field Study"
"Solana™ Trichomonas Assay Field Study"
Status: Enrolling
Updated:  3/16/2018
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
"Solana™ Trichomonas Assay Field Study"
"Solana™ Trichomonas Assay Field Study"
Status: Enrolling
Updated: 3/16/2018
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
"Solana™ Trichomonas Assay Field Study"
"Solana™ Trichomonas Assay Field Study"
Status: Enrolling
Updated:  3/16/2018
University of North Carolina, Div. of Infectious Diseases
mi
from
Chapel Hill, NC
"Solana™ Trichomonas Assay Field Study"
"Solana™ Trichomonas Assay Field Study"
Status: Enrolling
Updated: 3/16/2018
University of North Carolina, Div. of Infectious Diseases
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
"Solana™ Trichomonas Assay Field Study"
"Solana™ Trichomonas Assay Field Study"
Status: Enrolling
Updated:  3/16/2018
University of Washington, Seattle
mi
from
Seattle, WA
"Solana™ Trichomonas Assay Field Study"
"Solana™ Trichomonas Assay Field Study"
Status: Enrolling
Updated: 3/16/2018
University of Washington, Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
NECCR Primacare Research, LLC
mi
from
Fall River, MA
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
NECCR Primacare Research, LLC
mi
from
Fall River, MA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Main Road Family Medicine
mi
from
South Westport, MA
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Main Road Family Medicine
mi
from
South Westport, MA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Essentia Institute of Rural Health
mi
from
Duluth, MN
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Essentia Institute of Rural Health
mi
from
Duluth, MN
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Regional Clinical Research, Inc.
mi
from
Endwell, NY
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Regional Clinical Research, Inc.
mi
from
Endwell, NY
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Harleysville Medical Associates
mi
from
Harleysville, PA
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Harleysville Medical Associates
mi
from
Harleysville, PA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Lincoln Primary Care
mi
from
Lincoln, RI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Lincoln Primary Care
mi
from
Lincoln, RI
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Miriam Hospital
mi
from
Providence, RI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Center for Medical Research LLC
mi
from
Providence, RI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Center for Medical Research LLC
mi
from
Providence, RI
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Ocean State Primary Care
mi
from
Westerly, RI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Ocean State Primary Care
mi
from
Westerly, RI
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Marshfield Clinic Research Institute
mi
from
Marshfield, WI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Marshfield Clinic Research Institute
mi
from
Marshfield, WI
Click here to add this to my saved trials
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors.
Status: Enrolling
Updated:  3/20/2018
Intermountain Medical Center
mi
from
Murray, UT
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors.
Status: Enrolling
Updated: 3/20/2018
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Safety and Efficacy of Eltrombopag at Escalated Doses
Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg
Status: Enrolling
Updated:  3/21/2018
Weill Cornell Medicine
mi
from
New York, NY
Safety and Efficacy of Eltrombopag at Escalated Doses
Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg
Status: Enrolling
Updated: 3/21/2018
Weill Cornell Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Washington,
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Orlando, FL
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Vero Beach, FL
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Boston, MA
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Annandale, VA
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Annandale, VA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Uniontown, PA
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Uniontown, PA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
San Diego, CA
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Stockbridge, GA
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Meridian, ID
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Meridian, ID
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Lewiston, ME
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Lewiston, ME
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Las Vegas, NV
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Charlotte, NC
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Salisbury, NC
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Salisbury, NC
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Richmond, VA
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Warwick, RI
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Warwick, RI
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Greer, SC
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Greer, SC
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  3/23/2018
GSK Investigational Site
mi
from
Tucson, AZ
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 3/23/2018
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Prospective Assessment in Newborns for Diabetes Autoimmunity
1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D
Status: Enrolling
Updated:  3/26/2018
University of Florida
mi
from
Gainesville, FL
Prospective Assessment in Newborns for Diabetes Autoimmunity
1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D
Status: Enrolling
Updated: 3/26/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Prospective Assessment in Newborns for Diabetes Autoimmunity
1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D
Status: Enrolling
Updated:  3/26/2018
Medical University of South Carolina
mi
from
Charleston, SC
Prospective Assessment in Newborns for Diabetes Autoimmunity
1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D
Status: Enrolling
Updated: 3/26/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Prospective Assessment in Newborns for Diabetes Autoimmunity
1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D
Status: Enrolling
Updated:  3/26/2018
University of South Carolina
mi
from
Columbia, SC
Prospective Assessment in Newborns for Diabetes Autoimmunity
1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D
Status: Enrolling
Updated: 3/26/2018
University of South Carolina
mi
from
Columbia, SC
Click here to add this to my saved trials
Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
Prospective Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
Status: Enrolling
Updated:  3/26/2018
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
Prospective Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
Status: Enrolling
Updated: 3/26/2018
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit
Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit
Status: Enrolling
Updated:  3/27/2018
Surgical Intensive Care Unit, The Methodist Hospital
mi
from
Houston, TX
Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit
Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit
Status: Enrolling
Updated: 3/27/2018
Surgical Intensive Care Unit, The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials